RxDoctor Payments Data

Joseph Slomowits, MD

Internal Medicine · Brooklyn, NYNPI 1134212053

Payments from drug & device makers

$1,680in general payments, 2019–2025

Across 82 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$282
  • Johnson & Johnson$209
  • Merck$203
  • Pfizer$202
  • AbbVie$202
  • Novo Nordisk$135
  • plus $447 from 15 others

What the payments were for

  • Food & beverage$1,680100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,680 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$539,868
Medicare patients
357
Services billed
12,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$102,019
JardianceEmpagliflozin91$81,492
LeukineSargramostim14$78,592
EliquisApixaban98$65,963
JanuviaSitagliptin Phosphate63$48,461
MyrbetriqMirabegron38$23,960
Metformin Er GastricMetformin Hcl14$21,441
EntrestoSacubitril/Valsartan20$21,288
XareltoRivaroxaban26$20,958
MounjaroTirzepatide16$15,855
LinzessLinaclotide24$15,743
TrulicityDulaglutide15$14,635
Diclofenac Sodium30$12,840
VascepaIcosapent Ethyl12$10,699
TradjentaLinagliptin11$9,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$135$104,578112 claims
Boehringer IngelheimJardiance, Tradjenta$18$91,234102 claims
PfizerEliquis$202$65,96398 claims
MerckJanuvia$203$48,46163 claims
Lilly USA, LLCMounjaro, Trulicity$282$30,49031 claims
Astellas Pharma US IncMyrbetriq$53$23,96038 claims
Johnson & JohnsonXarelto$209$20,95826 claims
AbbVieLinzess, Synthroid$202$18,42654 claims
Kowa Pharmaceuticals America, Inc.Bystolic$20$5,76913 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$28$1,439159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →